Editorial Board — Medscape Oncology

Board Members

  • Harold J. Burstein, MD, PhD
    • Harvard Medical School
      Dana-Farber Cancer Institute
      Boston, Massachusetts
  • Bruce D. Cheson, MD
    • Georgetown University
      Georgetown University Hospital
      Washington, DC
  • Avraham Eisbruch, MD
    • University of Michigan
      University of Michigan Hospital
      Ann Arbor, Michigan
  • David J. Kerr, MD
    • University of Oxford
      Oxford Cancer Centre
      Oxford, United Kingdom
  • Mark G. Kris, MD
    • Memorial Sloan-Kettering Cancer Center
      Weill Cornell Medical College
      New York, New York
  • Corey J. Langer, MD
    • University of Pennsylvania Medical School
      Abramson Cancer Center
      Philadelphia, Pennsylvania
  • Maurie Markman, MD
    • Drexel University College of Medicine
      Cancer Treatment Centers of America
      Philadelphia, Pennsylvania
  • John L. Marshall, MD
    • Georgetown University
      Washington, DC
  • Kathy D. Miller, MD
    • Indiana University School of Medicine
      Indiana University Simon Cancer Center
      Indianapolis, Indiana
  • Richard M. Stone, MD
    • Harvard Medical School
      Dana-Farber Cancer Institute
      Boston, Massachusetts
  • Nicholas J. Vogelzang, MD
    • University of Nevada School of Medicine
      US Oncology Research
      Comprehensive Cancer Centers of Nevada
      Las Vegas, Nevada
  • Louis M. Weiner, MD
    • Georgetown University
      Georgetown University Medical Center
      Washington, DC
  • John R. Wingard, MD
    • University of Florida
      Shands Cancer Hospital at the University of Florida
      Gainesville, Florida
 

Board Member Details

Harold J. Burstein, MD, PhD
Harold J. Burstein, MD, PhD

Associate Professor of Medicine, Harvard Medical School; Institute Physician, Dana-Farber Cancer Institute, Boston, Massachusetts

Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.

Bruce D. Cheson, MD
Bruce D. Cheson, MD

Professor of Medicine, Department of Hematology-Oncology; Deputy Chief, Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC

Bruce D. Cheson, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Celgene; Astellas; Pharmacyclics; Gilead; Roche-Genentech; AbbVie

Avraham Eisbruch, MD
Avraham Eisbruch, MD

Professor, University of Michigan; Associate Chair, University of Michigan Hospital, Ann Arbor, Michigan

Avraham Eisbruch, MD, has disclosed the following relevant financial relationships:
Received research grant from: National Institutes of Health (RO1)

David J. Kerr, CBE, MD, DSc, FRCP, FMedSci
David J. Kerr, MD

Professor, Nuffield Department of Clinical Laboratory Science, University of Oxford; Professor of Cancer Medicine, Oxford Cancer Centre, Oxford, United Kingdom

David Kerr, CBE, MD, DSc, FRCP, FMedSci, has disclosed the following relevant financial relationships:
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Oxford Cancer Biomarkers; OxOnc; Celleron Therapeutics Ltd; Cancer Care Commission
Serve(d) as a speaker or a member of a speakers bureau for: Merck-Serono
Received research grant from: Roche; Bayer
Have a 5% or greater equity interest in: Oxford Cancer Biomarkers; Celleron Therapeutics Ltd; Cancer Care Commission
Received income in an amount equal to or greater than $250 from: Oxford Cancer Biomarkers; OxOnc; Celleron Therapeutics

Mark G. Kris, MD
Mark G. Kris, MD

Professor of Medicine, Weill Cornell Medical College; Attending Physician, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York

Mark G. Kris, MD, has disclosed no relevant financial relationships.

,
Corey J. Langer, MD
Corey J. Langer, MD

Professor of Medicine, University of Pennsylvania Medical School; Director, Thoracic Oncology, Abramson Cancer Center, Philadelphia, Pennsylvania

Corey J. Langer, MD, has disclosed the following relevant financial relationships:
Received institutional grant/research support from: Bristol-Myers Squibb Company; Pfizer Inc; Eli Lilly and Company; Genentech, Inc.; OSI Pharmaceuticals, Inc.; Merck & Co. Inc; GlaxoSmithKline; Nektar; Clovis Oncology
Served as a scientific advisor for: Bristol-Myers Squibb Company; ImClone Systems Incorporated; sanofi-aventis; Pfizer Inc; Eli Lilly and Company; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Genentech, Inc.; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Abbott Laboratories; Morphobiotek, Inc.; Biodesix; Clariant; CarisDx; Vertex; Synta Pharmaceuticals Corp.; Celegene; Boehringer Ingelheim Pharmaceuticals, Inc.; AbbVie; Clovis Oncology; Merck & Co. Inc
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; OSI Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; ImClone Systems Incorporated (all curtailed as of 12/10)
Data Safety Monitoring Committee Member: Eli Lilly and Company; Amgen Inc; Synta Pharmaceuticals Corp.; Agennix; Peregrine; SWOG; Incyte Corporation
CME: Imedex; Physicians Education Resource; TRM Oncology

Maurie Markman, MD
Maurie Markman, MD

Clinical Professor, Drexel University College of Medicine; President, Medical & Science, Cancer Treatment Centers of America, Philadelphia, Pennsylvania

Maurie Markman, MD, has disclosed the following relevant financial relationships:
Received income in an amount equal to or greater than $250 from: Genentech, Inc; AstraZeneca Pharmaceuticals LP; Celgene; Clovis; Amgen

John L. Marshall, MD
John L. Marshall, MD

Professor of Medicine; Chief, Division of Hematology-Oncology; Director, Clinical Research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

John L. Marshall, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Taiho Oncology; Celgene Corporation; Caris Life Sciences
Serve(d) as a speaker or member of a speakers bureau for: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Taiho Oncology; Celgene Corporation; Caris Life Sciences
Received research grant from: Genentech, Inc; Amgen Inc; Bayer HealthCare Pharmaceuticals; Taiho Oncology; Celgene Corporation; Caris Life Sciences

Kathy D. Miller, MD
Kathy D. Miller, MD

Professor, Department of Medicine (Hematology-Oncology), Indiana University Simon Cancer Center; Co-Director, Breast Cancer Program, Indiana University Simon Cancer Center, Indianapolis, Indiana

Kathy D. Miller, MD, has disclosed no relevant financial relationships.

Richard M. Stone, MD
Richard M. Stone, MD

Professor of Medicine, Harvard Medical School; Director, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, Massachusetts

Richard M. Stone, MD, has disclosed the following relevant financial relationships:
Received research grant from: Novartis Pharmaceuticals Corporation
Received income in an amount equal to or greater than $250 from: Amgen Inc; Abbvie; Roche; Seattle Genetics, Inc; Bristol-Myers Squibb Company; Celator

Nicholas J. Vogelzang, MD
Nicholas J. Vogelzang, MD

Research Medical Director, US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Nicholas J. Vogelzang, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen Inc.; Janssen Biotech, Inc; BIND Biosciences; AVEO
Serve(d) as a speaker or a member of a speakers bureau for: Dendreon Corporation; Bayer HealthCare Pharmaceuticals; Medivation, Inc.; Caris Molecular Profiling Institute; Millennium Pharmaceuticals, Inc; sanofi-aventis; GlaxoSmithKline
Received honoraria from: DAVA Oncology; Mannkind; UpToDate; Abbvie; Bavarian Nordic; Endocyte Stock: Caris Life Sciences
Received research funding from: PAREXEL International; Progenics Pharmaceuticals, Inc; Exelixis; US Oncology; Viamet Pharmaceuticals; Endocyte; GlaxoSmithKline
Received travel, accommodations, or expenses from: Genentech/Roche; Celgene; US Oncology; Dendreon; Novartis Pharmaceuticals Corporation; Pfizer Inc; Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Inc.; Exelixis

Louis M. Weiner, MD
Louis M. Weiner, MD

Francis L. and Charlotte G. Gragani Chair and Professor, Department of Oncology, Georgetown University Medical Center; Clinical Director of Cancer Services, Georgetown University Hospital, Washington, DC

Louis M. Weiner, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: AbbVie Inc.; Genentech BioOncology; Merck & Co., Inc.; Mylan Laboratories Inc.; Novartis Pharmaceuticals
Serve(d) on the scientific advisory board for: Celldex Therapeutics, Inc.; Jounce Therapeutics, Inc.; Merrimack Pharmaceuticals, Inc.
Serve(d) on the external advisory board for: CytomX Therapeutics, Inc.
Investment in: Targeted Diagnostics & Therapeutics, Inc.

John R. Wingard, MD
John R. Wingard, MD

Professor of Medicine, University of Florida; Director, Bone Marrow Transplant Program, Shands Hospital at the University of Florida Health, Gainesville, Florida

John R. Wingard, MD, has disclosed the following relevant financial relationships:
Serve(d) on the Board of Directors for: National Marrow Donor Program
Received consultant fees from: Astellas Pharma, Inc.; Merck & Co., Inc; Gilead Sciences, Inc.; Fate Therapeutics, Inc.; Shire; Ansun BioPharma